These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 32612066)

  • 1. Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
    Isshiki M; Sakuma I; Hayashino Y; Sumita T; Hara K; Takahashi K; Shiojima I; Satoh-Asahara N; Kitazato H; Ito D; Saito D; Hatano M; Ikegami Y; Iida S; Shimada A; Noda M
    Endocr J; 2020 Nov; 67(11):1127-1138. PubMed ID: 32612066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
    Heerspink HJ; Johnsson E; Gause-Nilsson I; Cain VA; Sjöström CD
    Diabetes Obes Metab; 2016 Jun; 18(6):590-7. PubMed ID: 26936519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
    Weber MA; Mansfield TA; Alessi F; Iqbal N; Parikh S; Ptaszynska A
    Blood Press; 2016; 25(2):93-103. PubMed ID: 26623980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers.
    Spannella F; Giulietti F; Balietti P; Borioni E; Lombardi FE; Ricci M; Cocci G; Landi L; Sarzani R
    J Hypertens; 2017 Nov; 35(11):2315-2322. PubMed ID: 28614094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
    Browne GA; Griffin TP; O'Shea PM; Dennedy MC
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
    Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
    Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of salt intake on target organ damages in treated hypertensive patients.
    Ohta Y; Tsuchihashi T; Kiyohara K
    Clin Exp Hypertens; 2012; 34(5):316-20. PubMed ID: 22804491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
    Sen T; Scholtes R; Greasley PJ; Cherney DZI; Dekkers CCJ; Vervloet M; Danser AHJ; Barbour SJ; Karlsson C; Hammarstedt A; Li Q; Laverman GD; Bjornstad P; van Raalte DH; Heerspink HJL
    Diabetes Obes Metab; 2022 Aug; 24(8):1578-1587. PubMed ID: 35478433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slowing Progression in CKD: DAPA CKD and Beyond.
    Larmour K; Levin A
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1117-1119. PubMed ID: 33692116
    [No Abstract]   [Full Text] [Related]  

  • 15. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
    Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin-angiotensin-aldosterone system.
    Libianto R; Jerums G; Lam Q; Chen A; Baqar S; Pyrlis F; Macisaac RJ; Moran J; Ekinci EI
    Clin Sci (Lond); 2014 Jan; 126(2):147-54. PubMed ID: 23875766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
    Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
    J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus.
    Griffin TP; Islam MN; Blake L; Bell M; Griffin MD; O'Shea PM
    Horm Metab Res; 2019 Feb; 51(2):91-99. PubMed ID: 30522145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data.
    Henney AE; Riley DR; Heague M; Hydes TJ; Anson M; Alam U; Cuthbertson DJ
    Diabetes Obes Metab; 2024 Oct; 26(10):4665-4673. PubMed ID: 39109451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment.
    Sarzani R; Guerra F; Mancinelli L; Buglioni A; Franchi E; Dessì-Fulgheri P
    Am J Hypertens; 2012 Jul; 25(7):818-26. PubMed ID: 22552267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.